In humans, CRTAP mutations are associated with the clinical spectrum of recessive OI, ranging from neonatal lethal cases (OI type II) to a milder phenotype (OI type VII), depending upon the nature of mutation. Here, CRTAP is linked to osteogenesis imperfecta.